NASDAQ:ARTL Artelo Biosciences Q3 2026 Earnings Results & Report $2.07 -0.03 (-1.43%) Closing price 11/13/2026 03:57 PM EasternExtended Trading$2.04 -0.02 (-1.21%) As of 11/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Artelo Biosciences beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$3.19 versus the -$7.02 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Artelo Biosciences EPS ResultsActual EPS-$3.19Consensus EPS -$7.02Beat/MissBeat by +$3.83One Year Ago EPSN/AEPS Beat Rate3 of last 4 quartersArtelo Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Artelo Biosciences Q3 2026 Earnings FAQ Did Artelo Biosciences beat earnings estimates for Q3 2026? Artelo Biosciences (NASDAQ:ARTL) reported earnings of -$3.19 per share for Q3 2026, beating the consensus estimate of -$7.02. The report was announced on Thursday, November 12, 2026. Artelo Biosciences Earnings HeadlinesArtelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial ResultsNovember 12 at 10:09 AM | markets.businessinsider.comArtelo Biosciences (NASDAQ:ARTL) Shares Down 5.4% - Should You Sell?November 5, 2026 | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Artelo Biosciences consensus price target increased 2,600% to $826.20November 2, 2026 | msn.comArtelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on PainOctober 29, 2026 | globenewswire.comArtelo Biosciences to Present ART26.12 Data at IASP World Congress on Pain as First Selective FABP5 Inhibitor Advances Toward MAD StudyOctober 26, 2026 | quiverquant.comQSee More Artelo Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email. Email Address About Artelo BiosciencesArtelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a biological signaling network involved in areas such as pain, appetite, inflammation and cancer. The company’s programs are designed to address unmet medical needs in oncology and other therapeutic areas. Artelo’s development pipeline has included ART27.13, a peripherally restricted cannabinoid receptor type 1 agonist being investigated for cancer-related anorexia and cachexia. The company has also developed ART26.12, a selective fatty acid-binding protein 5 inhibitor with potential applications in oncology and pain, and ART12.11, a proprietary cannabidiol-based therapeutic candidate. The company was established in 2011 and is headquartered in San Diego, California. Artelo has conducted research and development activities in collaboration with organizations in the United States and the United Kingdom. Its leadership has included Gregory D. Gorgas, who has served as president and chief executive officer.View Artelo Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
